Skip to content

Effect of conbercept on the microRNAs of proliferative diabetic retinopathy

Effect of conbercept on intraocular microRNAs in patients with proliferative diabetic retinopathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085393
Enrollment
Unknown
Registered
2024-06-06
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proliferative diabetic retinopathy

Interventions

control group (idiopathic macular hole):None
Disease group (Untreated PDR):None
treatment group (PDR after intravitreal injection of conbercept):None

Sponsors

Wuhan Aier Eye Hanyang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: The diagnosis of PDR was based on the American Academy of Ophthalmology Clinical guidelines for diabetic retinopathy. Patients with any of the following findings were considered to be at the stage of PDR: neovascularization, vitreous hemorrhage, or preretinal hemorrhage.

Exclusion criteria

Exclusion criteria: Previous history of ocular trauma, surgery and retinal laser photocoagulation, serious heart, liver, kidney diseases, infection, glaucoma and retinal vascular diseases such as hypertensive retinopathy, retinal vein occlusion, age-related macular degeneration, etc.

Design outcomes

Primary

MeasureTime frame
microRNA;

Countries

China

Contacts

Public ContactLong He

Wuhan Aier Eye Hanyang Hospital

1227341049@qq.com+86 136 9410 4883

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026